Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 60Breast Neoplasms 21Neoplasms 19Fallopian Tube Neoplasms 16Prostatic Neoplasms 15Neoplasm Metastasis 9Pancreatic Neoplasms 8Endometrial Neoplasms 8Glioblastoma 7Triple Negative Breast Neoplasms 6Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Small Cell Lung Carcinoma 4Glioma 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Mesothelioma 3Melanoma 3Head and Neck Neoplasms 3Cystadenocarcinoma, Serous 3Cholangiocarcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Sarcoma 2Prostatic Neoplasms, Castration-Resistant 2Ovarian Diseases 2Mesothelioma, Malignant 2

Interventions

Fulvestrant 10Everolimus 6Cetuximab 6Alpelisib 6Letrozole 4serabelisib 3ribociclib 3palbociclib 3duvelisib 3berzosertib 3Paclitaxel 3PX-866 3NVP-BKM120 3Irinotecan 3sapanisertib 2pembrolizumab 2parsaclisib 2olaparib 2binimetinib 2Topotecan 2Gemcitabine 2Carboplatin 2volagidemab 1venetoclax 1tivozanib 1tipifarnib 1tanezumab 1talazoparib 1sotorasib 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hereditary Sensory and Autonomic Neuropathies × niraparib × Clear all
NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

EMD Serono

Phase 2 Active not recruiting
63 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡